Akebia Therapeutics (AKBA) Cash from Operations (2013 - 2026)

Akebia Therapeutics (AKBA) has 14 years of Cash from Operations data on file, last reported at 21207000.0 in Q1 2026.

• Cash from Operations for Q1 2026 came in at 21207000.0, down 56.08% year-over-year; the trailing twelve-month figure through Mar 2026 was 60372000.0 (up 273.41% YoY), and the FY2025 annual result was 67992000.0, up 267.22% from the prior year.
• Cash from Operations fell to 21207000.0 in Q1 2026 per AKBA's latest filing, from 31129000.0 in the prior quarter.
• Over five years, Cash from Operations peaked at 33805000.0 in Q3 2022 and troughed at 54679000.0 in Q4 2022.
• A 5-year average of 5318352.94 and a median of 7167000.0 in 2023 frame the typical range for Cash from Operations.
• The sharpest annual moves came in 2024 and 2025: Cash from Operations slumped 377.38% in 2024, then surged 797.02% in 2025.
• A 5-year view of Cash from Operations shows it stood at 54679000.0 in 2022, then surged by 95.78% to 2308000.0 in 2023, then slumped by 93.5% to 4466000.0 in 2024, then surged by 797.02% to 31129000.0 in 2025, then slumped by 168.13% to 21207000.0 in 2026.
• Business Quant data shows AKBA's Cash from Operations at 21207000.0 in Q1 2026, 31129000.0 in Q4 2025, and 28105000.0 in Q3 2025.